Brown Capital Management LLC Increases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Brown Capital Management LLC boosted its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 13.3% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,463 shares of the medical research company’s stock after acquiring an additional 1,699 shares during the quarter. Brown Capital Management LLC’s holdings in Charles River Laboratories International were worth $2,919,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CRL. Private Advisor Group LLC boosted its stake in shares of Charles River Laboratories International by 15.4% in the 1st quarter. Private Advisor Group LLC now owns 1,331 shares of the medical research company’s stock valued at $378,000 after buying an additional 178 shares during the period. Panagora Asset Management Inc. raised its position in shares of Charles River Laboratories International by 236.5% during the 1st quarter. Panagora Asset Management Inc. now owns 2,722 shares of the medical research company’s stock worth $773,000 after acquiring an additional 1,913 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Charles River Laboratories International by 6.6% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,752 shares of the medical research company’s stock worth $1,917,000 after acquiring an additional 418 shares in the last quarter. Great West Life Assurance Co. Can raised its position in shares of Charles River Laboratories International by 0.4% during the 1st quarter. Great West Life Assurance Co. Can now owns 25,049 shares of the medical research company’s stock worth $7,465,000 after acquiring an additional 107 shares in the last quarter. Finally, Raymond James Trust N.A. raised its position in shares of Charles River Laboratories International by 33.7% during the 1st quarter. Raymond James Trust N.A. now owns 1,525 shares of the medical research company’s stock worth $433,000 after acquiring an additional 384 shares in the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $199.74 on Friday. Charles River Laboratories International, Inc. has a 12 month low of $181.22 and a 12 month high of $262.00. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.49 and a quick ratio of 1.21. The business has a 50 day simple moving average of $206.63 and a 200-day simple moving average of $203.42. The stock has a market capitalization of $10.24 billion, a PE ratio of 21.18, a price-to-earnings-growth ratio of 1.83 and a beta of 1.33.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, August 9th. The medical research company reported $2.69 EPS for the quarter, topping the consensus estimate of $2.63 by $0.06. Charles River Laboratories International had a return on equity of 18.99% and a net margin of 11.58%. The business had revenue of $1.06 billion during the quarter, compared to analysts’ expectations of $1.05 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. The company’s quarterly revenue was up 8.9% compared to the same quarter last year. Equities analysts predict that Charles River Laboratories International, Inc. will post 10.48 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Sunday. Citigroup lowered Charles River Laboratories International from a “buy” rating to a “neutral” rating and cut their target price for the stock from $260.00 to $225.00 in a research report on Monday, July 10th. Bank of America lifted their price target on Charles River Laboratories International from $235.00 to $245.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Finally, JPMorgan Chase & Co. lifted their price target on Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Thursday, August 10th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of “Moderate Buy” and an average price target of $247.80.

Insider Buying and Selling

In related news, CAO Michael Gunnar Knell sold 1,471 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $216.54, for a total transaction of $318,530.34. Following the transaction, the chief accounting officer now owns 9,940 shares of the company’s stock, valued at $2,152,407.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CAO Michael Gunnar Knell sold 1,471 shares of the company’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $216.54, for a total transaction of $318,530.34. Following the transaction, the chief accounting officer now owns 9,940 shares of the company’s stock, valued at $2,152,407.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP William D. Barbo sold 5,763 shares of the company’s stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $217.24, for a total value of $1,251,954.12. Following the completion of the sale, the vice president now directly owns 3,592 shares in the company, valued at approximately $780,326.08. The disclosure for this sale can be found here. Insiders have sold 7,934 shares of company stock valued at $1,722,048 over the last quarter. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).